Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide

Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, Chao Liang, Hao Wang, Yan Chen, John L. Silberstein, Danilo Piana, Zhao Lai, Yidong Chen, William B. Isaacs, Jun Luo

Research output: Contribution to journalArticlepeer-review

67 Scopus citations

Abstract

To determine whether and how germline DNA-repair gene mutations influence clinical outcomes to abiraterone or enzalutamide in patients with castration-resistant prostate cancer (CRPC), we performed germline genotyping for 50 DNA-repair genes using blood samples from 172 patients with CRPC beginning first-line systemic therapy with abiraterone or enzalutamide. We discovered that the presence of germline DNA-repair gene defects (particularly mutations in the BRCA1/2 and ATM genes) were associated with better outcomes to abiraterone and enzalutamide.

Original languageEnglish (US)
Pages (from-to)218-225
Number of pages8
JournalEuropean Urology
Volume74
Issue number2
DOIs
StatePublished - Aug 2018

Keywords

  • Abiraterone
  • DNA repair
  • Enzalutamide
  • Germline
  • Mutation

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide'. Together they form a unique fingerprint.

Cite this